Tamoxifen

← All agents

Catalog entry human-reviewed · each study below is labeled with how it was published · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

Get cited updates on Tamoxifen

A monthly email when the research changes — $10/mo. Manage follows

Follow Tamoxifen

Evidence at a glanceHuman · observationalMixed results⚠ Studies disagree

5 published studies tagged to this agent1 human studies approved & graded (trial, observational, or meta-analysis)

Why this grade?

Human · observational — Human observational evidence only — no trials.

1 human · 0 animal · 0 lab · 4 review/other
Most authoritative study: Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer
Studies disagree on the reported direction (conflict flagged).
Findings conflict across studies
Effect sizes reported in only 2 of 5 studies

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

Auto-discovered · not yet curatedtamoxifen

Educational only, not medical advice. OncoForge makes no claim that Tamoxifen treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

Auto-discovered from 1 recent study; not yet curated.

Research

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CancerHuman evidenceMechanismSafetyTrial

Endometrial Carcinosarcoma1—2—

Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus? Human · observationalInconclusive
Endometrial müllerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer Case reportInconclusive

Uterine Carcinosarcoma (Malignant Mixed MüLlerian Tumor)1—1—

Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus? Human · observationalInconclusive

Breast Cancer—11—

Tamoxifen and Endometrial Cancer: A Janus-Headed Drug ReviewMixed results
Endometrial müllerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer Case reportInconclusive

Advanced Or Metastatic High Grade Epithelial Ovarian Cancer—1—1

Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer ReviewInconclusive

Cervical Squamous Cell Carcinoma—1——

Anti-Estrogen Therapy Achieves Complete Remission and Stability in Recurrent Cervical Cancer: A Case Study Case reportReported positive

Endometrial Cancer—1——

Tamoxifen and Endometrial Cancer: A Janus-Headed Drug ReviewMixed results

High Grade Epithelial Ovarian Cancer—1—1

Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer ReviewInconclusive

Ovarian Epithelial Carcinoma—1—1

Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer ReviewInconclusive

Reported figures

Study mix

5 published studies by what they were done in. Lab and animal findings often do not carry over to people.

1 Human4 Review/other

Reported directionReported positive1Mixed results1Inconclusive3

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline

Meta-analysis

Systematic review

Randomized trial

Clinical trial

Observational

Case report

Review

Preclinical

Other

5 studies1 human4 review/other

Tracking 5 published studies of Tamoxifen: 1 in humans, 4 reviews/other.

Reported direction across studies: 1 positive, 1 mixed, 3 inconclusive.

Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.

These counts summarize what the studies reported; they are not a measure of whether Tamoxifen works.

Cancers named in these studies

breast cancer (2)endometrial carcinosarcoma (2)cervical squamous cell carcinoma (1)advanced or metastatic high-grade epithelial ovarian cancer (1)high-grade epithelial ovarian cancer (1)ovarian epithelial carcinoma (1)endometrial cancer (1)uterine carcinosarcoma (malignant mixed Müllerian tumor) (1)

Conflicting evidence

Reported positive (1)

Anti-Estrogen Therapy Achieves Complete Remission and Stability in Recurrent Cervical Cancer: A Case Study
Case report · Limited evidence · Jan 2025

Negative or mixed (1)

Tamoxifen and Endometrial Cancer: A Janus-Headed Drug
Review · Moderate evidence · Sep 2020

All studies

Case reportReported positiveLimited evidenceTier 3 · early humann = 1

Anti-Estrogen Therapy Achieves Complete Remission and Stability in Recurrent Cervical Cancer: A Case Study

The American journal of case reports · Jan 2025 · case report

Tamoxifencervical squamous cell carcinoma

An 84-year-old woman with recurrent cervical squamous cell carcinoma received anti-estrogen therapy (tamoxifen, then letrozole) instead of salvage chemotherapy because of comorbidities. Complete remission was observed after tamoxifen; when the tumor relapsed 40 months later she was switched to letrozole, which was associated with a marked drop in SCC-Ag and disease stability for 29 months. The patient subsequently died of noncancer causes after a total of 5 years and 9 months on anti-estrogen therapy.

Reported effects: time to central recurrence after chemoradiotherapy 9 mo, n=1 · time to relapse after tamoxifen 40 mo, n=1 · +2 more

Key findings

Central recurrence was found 9 months after initial concurrent chemoradiotherapy.
Complete remission was noted after tamoxifen therapy.
The cervical cancer relapsed 40 months after tamoxifen use, and therapy was shifted to letrozole.
SCC-Ag level decreased dramatically after letrozole therapy.
Disease stability was achieved for 29 months after letrozole.
After 5 years and 9 months of anti-estrogen use only, the patient died of noncancer-related pneumonia and heart failure.

Limitations: Single-patient case report — no control group and results may not generalize.; No dose, schedule, or safety/adverse-event details for tamoxifen or letrozole provided in the abstract.; Observational and retrospective description; causality between anti-estrogen therapy and outcomes cannot be established.; No information on tumor hormone-receptor status or other biomarkers besides SCC-Ag in the abstract..

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewTrialInconclusiveLimited evidenceTier 4 · clinicaln = 11

Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer

Revista colombiana de obstetricia y ginecologia · Jun 2024 · expert consensus / practice guideline based on literature review

Bevacizumab Anastrozole Cisplatin Gemcitabine Topotecan Olaparib Niraparib Carboplatin Liposomal-doxorubicin Paclitaxel Tamoxifen Rucaparibadvanced or metastatic high-grade epithelial ovarian cancerhigh-grade epithelial ovarian cancerovarian epithelial carcinoma

This paper is an expert consensus, not a clinical study of a single drug. Eleven specialists reviewed the literature and issued recommendations for managing advanced or metastatic high-grade epithelial ovarian cancer, including surgery, chemotherapy, genetic testing, bevacizumab, and PARP inhibitors. It does not report new patient outcomes from a trial. The document mainly summarizes what the panel suggested based on existing guidelines and evidence.

Studied with: platinum-based chemotherapy, bevacizumab, paclitaxel, carboplatin.

Key findings

The panel suggested primary cytoreductive surgery as the initial approach when complete resection is feasible.
Neoadjuvant chemotherapy followed by interval surgery was suggested when complete cytoreduction is unlikely or the patient has poor functional status/comorbidities.
Bevacizumab was suggested with platinum-based chemotherapy for high-risk disease, with maintenance only if it was part of first-line therapy.
PARP inhibitors (olaparib, niraparib, rucaparib) were suggested as maintenance in selected BRCA/HRD-defined groups.
For platinum-resistant relapse, sequential non-platinum single-agent chemotherapy and best supportive care for poor performance status were suggested.

Limitations: This is a consensus statement/practice guideline, not an original comparative trial.; No new efficacy or safety data are reported in the abstract.; Recommendations are based on literature review and expert agreement, so they are subject to guideline-selection and expert-opinion bias.; The abstract does not provide patient-level outcomes, follow-up, or effect estimates.; Several recommendations are conditional/suggested rather than based on direct evidence from this paper..

Provides management recommendations for advanced/metastatic epithelial ovarian cancer, including several anticancer agents and maintenance strategies.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewMixed resultsModerate evidenceTier 3 · early human

Tamoxifen and Endometrial Cancer: A Janus-Headed Drug

Cancers · Sep 2020 · narrative review

Tamoxifenendometrial cancerbreast cancer

This narrative review summarizes evidence that tamoxifen both increases the risk of endometrial cancer (estimated about 2–7 fold) and can have therapeutic activity in advanced or recurrent endometrial cancer with low toxicity. The authors discuss mechanistic explanations for these opposing effects, including tissue-specific ERα co-activator/co-repressor profiles and agonism at the membrane estrogen receptor GPER-1. The review does not present new primary data.

Reported effect: endometrial cancer risk (fold increase)

Key findings

Tamoxifen is used for treatment and prevention of ER-positive breast cancer.
Tamoxifen increases the risk of endometrial cancer by about 2-7 fold, and more aggressive types of EC with poor prognoses are observed in tamoxifen users.
Tamoxifen can be an efficacious treatment for advanced or recurrent endometrial cancer with low toxicity.
Differential agonist versus antagonist effects in endometrium are explained by tissue-specific expression of ERα co-activators and co-repressors and by tamoxifen acting as a pure agonist at GPER-1.

Limitations: Narrative review: no new primary data or pooled quantitative synthesis presented in the abstract.; Abstract does not state literature search or selection methods (potential selection bias).; Mechanistic explanations are proposed based on prior literature but not experimentally demonstrated within this article..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalSafetyInconclusiveLimited evidenceTier 3 · early humann = 21

Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus?

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · Jul 1995 · retrospective case series / archive review (single-center)

Tamoxifenuterine carcinosarcoma (malignant mixed Müllerian tumor)endometrial carcinosarcoma

The authors report a cluster of five uterine carcinosarcoma cases in 1993 at their center, four of whom had been prescribed long-term tamoxifen for breast cancer. A review of archives from 1983-1992 found two additional tamoxifen-associated carcinosarcoma cases among 16 total cases. In total six patients with carcinosarcoma had been taking tamoxifen; five had been on the drug at least six years and one had a three-year history. The authors raise the question of a possible association between long-term tamoxifen use and development of endometrial carcinosarcoma.

Reported effects: 1993 cluster cases 5 · 1993 cluster tamoxifen-associated cases 4 · +5 more

Key findings

A cluster of five patients with endometrial carcinosarcoma occurred at the center during 1993; four of these had been prescribed long-term tamoxifen for breast carcinoma.
Archive review for 1983-1992 revealed two further cases of uterine carcinosarcoma occurring in patients prescribed tamoxifen, from a total of 16 cases of this tumor.
Five of the six patients diagnosed with carcinosarcoma who had been taking tamoxifen had been maintained on the drug for at least 6 years; the other had a 3-year history of tamoxifen therapy.
The authors raise the question of an association between long-term tamoxifen treatment and development of endometrial carcinosarcoma following increased prescribing after 1984.

Limitations: Small number of cases (cluster and a few archival cases).; Single-center, retrospective, descriptive case series without a control group or denominator of tamoxifen-exposed patients.; No statistical analysis or incidence rates provided to quantify risk.; Potential reporting and selection bias; confounding factors not addressed (e.g., underlying breast cancer population)..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Case reportSafetyInconclusiveLimited evidenceTier 3 · early humann = 1

Endometrial müllerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · Mar 1995 · case report

Tamoxifenendometrial carcinosarcomabreast cancer

This is a single-case report of an 80-year-old woman who developed a heterologous mixed müllerian tumor (endometrial carcinosarcoma) in the fifth year after stopping tamoxifen. She had previously received tamoxifen for a total of 55 months over a 6-year period for breast cancer. The authors note that tamoxifen may have played a role but cannot exclude that the tumor arose de novo in an elderly woman and call for formal epidemiological study.

Key findings

Reported a case of heterologous mixed malignant müllerian tumor (endometrial carcinosarcoma) in an 80-year-old woman.
Patient had been diagnosed with breast cancer at age 69 and received tamoxifen for a total of 55 months over a 6-year period; the carcinosarcoma was diagnosed in the 5th year after cessation of tamoxifen therapy.
Authors state that while tamoxifen may have played a role, this histological tumor type can also arise de novo in elderly women and they recommend testing the etiologic hypothesis in a formal epidemiological investigation.

Limitations: Single patient (case report) — findings cannot establish causation or estimate risk.; No control or comparator group.; Potential confounding by advanced age; tumor may have arisen de novo.; Abstract provides limited clinical and pathological detail; no epidemiologic data presented..

AI summary of the abstract, human-reviewed · Aug 2026. Describes what this study reported, not medical advice. View on PubMed

What changed recently

The latest additions to Tamoxifen's evidence base, and anything that's been retracted.

Recently added

Anti-Estrogen Therapy Achieves Complete Remission and Stability in Recurrent Cervical Cancer: A Case Study Case report · added Sep 2026
Endometrial müllerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer Case report · added Aug 2026
Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus? Human · observational · added Jun 2026
Tamoxifen and Endometrial Cancer: A Janus-Headed Drug Review · added Jun 2026
Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer Review · added Jun 2026

Cancers where Tamoxifen reported positive results

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Preclinical only: lab / animal (1)

Cervical squamous cell carcinoma1 positive

Cited positive studies (1)

Anti-Estrogen Therapy Achieves Complete Remission and Stability in Recurrent Cervical Cancer: A Case Study Case report · Jan 2025

Evidence at a glance: Tamoxifen by cancer

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

Endometrial carcinosarcomaHuman · observationalInconclusive1 human

Human observational evidence only — no trials.

Largest credible effect: 1993 cluster cases 5 PMID 11578496 · effect sizes 2–16 across 7 studies

Most authoritative study: Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus?

Effect sizes reported in only 1 of 2 studies · All studies are small (n < 30).

Uterine carcinosarcoma (malignant mixed Müllerian tumor)Human · observationalInconclusive1 human

Human observational evidence only — no trials.

Largest credible effect: 1993 cluster cases 5 PMID 11578496 · effect sizes 2–16 across 7 studies

Most authoritative study: Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus?

Based on a single study.

Breast cancerInsufficient evidenceMixed results